Intercept Pharmaceuticals Stock News

The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.

Shares are taking a step back after the FDA rejected the company's NASH candidate.

(BFM Bourse) - L'agence américaine du médicament a refusé d'homologuer l'Ocaliva (acide obéticholique) d'Intercept pour le traitement de la fibrose du foie …

Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by stock analysts at Canaccord Genuity from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Briefing.

In a report released today, Jay Olson from Oppenheimer downgraded Intercept Pharma (ICPT – Research Report) to Hold, with a

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) is eyeing its worst day ever after the FDA declined to approve its liver treatment

The U.S. Food and Drug Administration declined to approve Intercept Pharmaceuticals Inc's therapy for a progressive liver disease, the company said on Monday, sending its shares down 37% before the be

Australia sees biggest daily rise in COVID-19 cases in two months Australia's second most populous state said on Monday it is considering reimposing social distancing restrictions after the country r

Intercept Pharmaceuticals shares fell after the FDA declined to clear its drug for a progressive liver disease.

Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat the fatty liver disease known as NASH.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $44.50 and last traded at $48.13, with a volume of 468

(Actualisé avec Facebook, Twitter et Snap, annonce de Coty, Intercept Pharmaceuticals, Gilead, cours en avant-Bourse) PARIS, 29 juin (Reuters) - Principales valeurs à suivre lundi à Wall Street

The FDA has sought additional post-interim analysis data from an ongoing late-stage trial in support of the marketing application as it found predicted effectiveness of the treatment failed to outwei

Intercept Pharmaceuticals Inc. shares undefined tumbled more than 30% in premarket trade Monday, after the company said it has received a U.S. Food and Drug...

Intercept Pharmaceuticals Inc. shares tumbled more than 30% in premarket trade Monday, after the company said it has received a U.S. Food and Drug Administration Complete Response Letter regarding it